BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off

BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given competitive Phase 1 data for BGE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98% IL-1β suppression and 86% median hsCRP reduction, with Phase 2 topline data expected in H2 2026. BIOA’s diversified pipeline includes ophthalmology and apelin-APJ pathway programs, plus partnerships with Novartis and Eli Lilly, supporting long-term optionality. With $74M cash and $245M in marketable securities, BIOA’s funding runway extends two years, positioning it to capitalize on positive future catalysts.